Skip to main content

Table 1 Hazard ratios for outcomes during follow-up by history of major PAD at baseline

From: Presentations of major peripheral arterial disease and risk of major outcomes in patients with type 2 diabetes: results from the ADVANCE-ON study

 

Baseline history of major PAD

Hazard ratios (major PAD vs. not)

No (n = 10,624)

Yes (n = 516)

Model 1

Model 2

HR

95 % CI

p

HR

95 % CI

p

All-cause mortality, n (%)

2101 (19.8)

164 (31.8)

1.57

1.33–1.84

<0.0001

1.35

1.15–1.60

0.0004

Major macrovascular events, n (%)

2025 (19.1)

141 (27.3)

1.59

1.34–1.88

<0.0001

1.47

1.23–1.75

<0.0001

Cardiovascular death, n (%)

904 (8.5)

84 (16.3)

1.99

1.59–2.49

<0.0001

1.75

1.39–2.21

<0.0001

Myocardial infarction, n (%)

665 (6.3)

57 (11.0)

1.76

1.34–2.31

<0.0001

1.58

1.19–2.09

0.001

Stroke, n (%)

924 (8.7)

44 (8.5)

1.24

0.92–1.68

0.16

1.19

0.87–1.62

0.28

Major clinical microvascular events, n (%)

763 (7.2)

44 (8.5)

1.43

1.05–1.94

0.02

1.31

0.96–1.78

0.09

Retinal photocoagulation or blindness, n (%)

632 (5.9)

37 (7.2)

1.48

1.06–2.07

0.02

1.39

0.99–1.95

0.05

End-stage renal disease or renal death, n (%)

160 (1.5)

8 (1.6)

1.15

0.56–2.34

0.71

0.96

0.46–1.97

0.90

  1. Model 1: adjusted for region of origin, sex, age, body mass index, systolic blood pressure, history of ever smoking, and study allocations. Model 2: adjusted as in model 1 plus duration of diabetes, HbA1c, waist circumference, heart rate, diastolic blood pressure, disturbance of 10-g monofilament sensation, absence of ankle and knee reflexes, estimated glomerular filtration rate (and its square for macrovascular analyses), total-, and HDL-cholesterol, triglycerides, use of antihypertensive, lipid lowering and antiplatelet drugs, and history of current alcohol drinking. p < 0.05 was significant